TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12929019

Group type: EXPERIMENTAL
Intervention: Histoacryl obliteration (group A, n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Propranolol administration (group B, n = 20)
Number of subjects: 41
Study: 10720043

Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg and 180 mg or 120 mg and 240 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nateglinide
Number of subjects: 24
Study: 8912778

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters (peak airway pressure, mean airway pressure, tidal volume)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall degree of air space disease
Number of subjects: 102
Study: 1547045

Group type: COMPARATOR
Intervention: 0.375% bupivacaine 10 ml alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine 10 ml combined with fentanyl 100 micrograms
Number of subjects: 30
Study: 4087369

Group type: EXPERIMENTAL
Intervention: Transfusion at 2 ml/min (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion at 5 ml/min (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion at 10 ml/min (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transfusion at 5 ml/min with 40 mg furosemide (Group D)
Number of subjects: 40
Study: 29846530

Group type: EXPERIMENTAL
Intervention: Andecaliximab 150 mg every 2 weeks (Q2W)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Andecaliximab 150 mg weekly (QW)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Andecaliximab 300 mg weekly (QW)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 27515515

Group type: EXPERIMENTAL
Intervention: Immediate-release melatonin (3 mg) administered daily at 21:00 ± 1 h from day 1 to day 28 of admission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25038509

Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SnCl2/AmF/NaF mouthrinse
Number of subjects: 15

Group type: COMPARATOR
Intervention: Negative control (non-fluoridated toothpaste)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Milk and CPP-ACP pastes (with or without fluoride)
Number of subjects: 15
Study: 22173265

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 21203698

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (830 nm, 15 mW, 12 J/cm²) daily from the 1st day until the end of RT for 5 consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aluminum hydroxide (AH) 310 mg/5 mL, 4 times/day throughout the duration of RT
Number of subjects: 25
Study: 18055958

Group type: EXPERIMENTAL
Intervention: 6 hours of reattribution training
Number of subjects: 141

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 141
Study: 14667696

Group type: EXPERIMENTAL
Intervention: Living kind concepts at different hierarchical levels (e.g. tree, oak)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Artifact concepts at different hierarchical levels
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adults' beliefs about within‐category similarity for concepts at different levels
Number of subjects: 3
Study: 11697755

Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (2 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (2 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam (2 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All routes (Intranasal, Intravenous, Intramuscular)
Number of subjects: 11
Study: 9068685

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 0
Study: 8180641

Group type: EXPERIMENTAL
Intervention: DTaP vaccine (0.5 mL, intramuscularly)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 172

Group type: COMPARATOR
Intervention: DTwP vaccine (0.5 mL, intramuscularly)
Number of subjects: 172

Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both DTaP and DTwP vaccines
Number of subjects: 172
Study: 3282463

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2 body surface area for 5 days by continuous intravenous infusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Calcitonin 8 IU/kg body weight every 6 hours for 5 days by intramuscular injection
Number of subjects: 164
Study: 28929258

Group type: EXPERIMENTAL
Intervention: Serotonin (5-HT) administered via intraventricular injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine (DA) administered via intraventricular injection
Number of subjects: 0
Study: 26659927

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (TERLI-INF group) at an initial dose of 2 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (TERLI-BOL group) at an initial dose of 0.5 mg every 4 hours
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (TERLI-INF and TERLI-BOL)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (TERLI-INF group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (TERLI-BOL group)
Number of subjects: 78
Study: 24621203

Group type: EXPERIMENTAL
Intervention: Bio‐Oss(®) Collagen
Number of subjects: 28

Group type: COMPARATOR
Intervention: No grafting (Control)
Number of subjects: 28
Study: 23586518

Group type: EXPERIMENTAL
Intervention: Cradle hold position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Side lying position
Number of subjects: 25
Study: 20350430

Group type: EXPERIMENTAL
Intervention: Gradual drug withdrawal after a 12-week treatment course
Number of subjects: 97

Group type: COMPARATOR
Intervention: Immediate drug withdrawal
Number of subjects: 97
Study: 18444136

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and selenium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16766604

Group type: EXPERIMENTAL
Intervention: Reminder procedure
Number of subjects: 6822

Group type: COMPARATOR
Intervention: No reminder procedure
Number of subjects: 6822
Study: 14650707

Group type: EXPERIMENTAL
Intervention: 20-mg enalapril tablets (test product)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 20-mg enalapril tablets (reference product)
Number of subjects: 14
Study: 10871571

Group type: EXPERIMENTAL
Intervention: Increased physical activity (treadmill walking to 1.8 times resting metabolic rate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sedentary conditions (1.4 times resting metabolic rate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sedentary conditions
Number of subjects: 6
Study: 9170118

Group type: EXPERIMENTAL
Intervention: Cyclandelate (Natil, 1,600 mg/day)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 1313163

Group type: EXPERIMENTAL
Intervention: Diet + glucomannan (approx. 4 g/die in 3 doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypocaloric diet therapy alone
Number of subjects: 50
Study: 6732250

Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no Misonidazole)
Number of subjects: 50
Study: 31204473

Group type: EXPERIMENTAL
Intervention: 3-Hydroxybenzo[a]pyrene glucuronide (BaP-3-G)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3-Hydroxybenzo[a]pyrene sulfate (BaP-3-S)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Urinary 3-OHBaP conjugates
Number of subjects: 150
Study: 29048708

Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol (MP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 120
Study: 26657945

Group type: EXPERIMENTAL
Intervention: Usual care plus a Diabetes Prevention Program (DPP)‐derived lifestyle intervention including mailed gestational weight gain recommendations and 13 telephone sessions between 6 weeks and 6 months postpartum.
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Usual care (mailed recommendations only).
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Usual care plus a Diabetes Prevention Program (DPP)‐derived lifestyle intervention.
Number of subjects: 2280
Study: 24643281

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 731
Study: 23588462

Group type: EXPERIMENTAL
Intervention: Diet A (40% carbohydrate/30% protein/30% fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diet B (55% carbohydrate/15% protein/30% fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diet A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diet B
Number of subjects: 40
Study: 20157316

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 6916

Group type: EXPERIMENTAL
Intervention: Inactivity
Number of subjects: 6916
Study: 17585375

Group type: EXPERIMENTAL
Intervention: Topical application of 0.5% timolol maleate
Number of subjects: 184

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 184
Study: 15867584

Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12488198

Group type: EXPERIMENTAL
Intervention: Formalized training sessions in clinical breast examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no formalized training)
Number of subjects: 0
Study: 10219865

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 1962
Study: 7887637

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy followed by chest irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternating chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy (increased dose intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs (CPT-11, taxol, axotere, vinorelbine, gemcitabine)
Number of subjects: 0
Study: 1919301

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral iron absorption
Number of subjects: 54
Study: 6228015

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30819228

Group type: EXPERIMENTAL
Intervention: mHealth intervention (reminder via cellphone text message/call or bottle-based flash/alarm, plus monthly counseling)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (standard counseling at routine monthly clinic visits)
Number of subjects: 80
Study: 29291768

Group type: EXPERIMENTAL
Intervention: Mothering from the Inside Out (MIO) treatment
Number of subjects: 84
Study: 27568506

Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation intervention combined with tele-health medication clinic for nicotine replacement therapy (NRT)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Referral to VA specialty smoking cessation care (control)
Number of subjects: 413
Study: 25306746

Group type: EXPERIMENTAL
Intervention: Amaltea goat's milk 200 ml/day during basic therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multispecies and multistrain RioFlora Balance probiotics in addition to goat's milk
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional basic dietary therapy
Number of subjects: 90
Study: 22068288

Group type: EXPERIMENTAL
Intervention: CRC screening information plus patient activation and barriers counseling
Number of subjects: 270

Group type: COMPARATOR
Intervention: CRC screening information
Number of subjects: 270
Study: 20153029

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler)
Number of subjects: 0
Study: 17389558

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 16685046

Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate diet (KLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonketogenic low-carbohydrate diet (NLC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both KLC and NLC diets
Number of subjects: 20
Study: 15459602

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2000 mg/dose, n = 95
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo, n = 85
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 10937408

Group type: EXPERIMENTAL
Intervention: Hepatitis B education/promotion curriculum package; administered over 4 class periods before vaccination.
Number of subjects: 15811

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned);
Number of subjects: 15811
Study: 8745328

Group type: EXPERIMENTAL
Intervention: bilayered cultured skin equivalent (Graftskin)
Number of subjects: 233
Study: 1569973

Group type: EXPERIMENTAL
Intervention: Standard therapy plus plasmapheresis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard therapy (prednisone and cyclophosphamide)
Number of subjects: 86
Study: 3865246

Group type: EXPERIMENTAL
Intervention: 0.5 mg DEX (dexamethasone) administered at 2300 h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0 mg DEX (dexamethasone) administered at 2300 h
Number of subjects: 40
Study: 30484332

Group type: EXPERIMENTAL
Intervention: US‐TAP block with 20 mL of 0.35% ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: No US‐TAP block
Number of subjects: 100
Study: 27511476

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/candesartan combinations
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Nifedipine GITS (N) monotherapy
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1801
Study: 25527666

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-infected infants
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-exposed infants
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations <10 ng/mL for HIV-infected infants
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations <10 ng/mL for HIV-exposed infants
Number of subjects: 1201
Study: 22812593

Group type: EXPERIMENTAL
Intervention: New moisturizer (CRM) containing a ceramide precursor applied for 27 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 0
Study: 21655990

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg o.d. for 1 week, then 1 g b.d. for 1 week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Internal control (no treatment for 1 week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Metformin (same dose regimen as above)
Number of subjects: 55
Study: 18708686

Group type: EXPERIMENTAL
Intervention: CHO+Pro (7.75% carbohydrate / 1.94% protein)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CHO+CHO (9.69% carbohydrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CHO (7.75% carbohydrate)
Number of subjects: 11
Study: 17002808

Group type: EXPERIMENTAL
Intervention: 8-item symptom index based on FACT-BRM scale
Number of subjects: 209
Study: 14601275

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg propofol (group A)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg propofol (group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: 0.4 mg/kg propofol (test-dose)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control value (baseline)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Correlation between test-dose and induction-dose
Number of subjects: 121
Study: 10854683

Group type: EXPERIMENTAL
Intervention: 5 mg isradipine plus 5 mg enalapril
Number of subjects: 102

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 102

Group type: COMPARATOR
Intervention: 10 mg isradipine
Number of subjects: 102

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 102

Group type: COMPARATOR
Intervention: isradipine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: combination of isradipine plus enalapril
Number of subjects: 102

Group type: COMPARATOR
Intervention: all groups
Number of subjects: 102
Study: 8617897

Group type: EXPERIMENTAL
Intervention: Exercise program (walking, wheelchair movement training, rowing exercise three times per week)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 97
Study: 1425871

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Acipimox (doses: 31.2, 62.5, 125.0, 250.0 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 6378522

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg t.i.d.) and dipyridamole (75 mg t.i.d.)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 231
Study: 30922083

Group type: EXPERIMENTAL
Intervention: Tooth-clenching task
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 70
Study: 29995589

Group type: EXPERIMENTAL
Intervention: Family-and-coping-oriented basic palliative homecare intervention (six visits within 15 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 26853497

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour treatment program (Cool Kids)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Homework adherence (measured as time spent doing homework assignments)
Number of subjects: 98
Study: 24525115

Group type: EXPERIMENTAL
Intervention: MOSF (15% Fish oil, 30% Medium‐chain triglycerides, 25% Olive oil, 30% Soybean oil) at 3.5 g kg(‐1) d(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MOSF (15% Fish oil) at 2.5 g kg(‐1) d(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MOSF (15% Fish oil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: S (100% Soybean oil)
Number of subjects: 80
Study: 22310249

Group type: EXPERIMENTAL
Intervention: 370 MBq ¹³¹I
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 555 MBq ¹³¹I
Number of subjects: 76
Study: 19642480

Group type: EXPERIMENTAL
Intervention: Healing Touch
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 784
Study: 17462166

Group type: EXPERIMENTAL
Intervention: Additional physiotherapy from a physiotherapy assistant for 1 hour per week for 6 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard physiotherapy plus family support worker visits
Number of subjects: 76
Study: 15235056

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 13
Study: 11243591

Group type: COMPARATOR
Intervention: 20 microg recombinant HBsAg (rHBsAg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 40 microg recombinant HBsAg (rHBsAg)
Number of subjects: 77
Study: 9203891

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 126

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 126
Study: 8388918

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) and Dactinomycin (AMD) for 17 weeks (S)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) and Dactinomycin (AMD) for 38 weeks (L)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: 20 Gy irradiation (R+) with VCR and AMD for 38 weeks
Number of subjects: 509

Group type: COMPARATOR
Intervention: No irradiation (R-) with VCR and AMD for 38 weeks
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Intensified VCR and AMD (INTVCR)
Number of subjects: 509

Group type: COMPARATOR
Intervention: VCR, AMD, and Adriamycin (ADRIA)
Number of subjects: 509
Study: 3551160

Group type: EXPERIMENTAL
Intervention: Multiple chemotherapeutic agents
Number of subjects: 81

Group type: COMPARATOR
Intervention: Single chemotherapeutic agents
Number of subjects: 81
Study: 31112370

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 232
Study: 28587665

Group type: EXPERIMENTAL
Intervention: PRACTICE clinical prediction rule (guidance on hospitalization for high risk patients >100 points and home discharge for low risk patients <75 points)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: PRACTICE clinical prediction rule
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard policy regarding hospital admission (control group)
Number of subjects: 370
Study: 27213447

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ supplementation with a standardized high-fat breakfast
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vitamin D₃ supplementation in fasting state
Number of subjects: 88
Study: 25086150

Group type: EXPERIMENTAL
Intervention: Online interactive training module
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional lecture‐based presentation
Number of subjects: 72
Study: 21853386

Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg i.v. for 7 days, followed by clodronate i.m. 100 mg for 14 days every 3 months (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hydroxychloroquine 400 mg daily for 30 days, followed by 200 mg daily for the next 11 months (Group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison between Clodronate (Group A) and Hydroxychloroquine (Group B)
Number of subjects: 38